利伐沙班与华法林预防心房颤动导管消融术后血栓事件的对比研究

Comparative study of rivaroxaban and warfarin prevention of thrombotic events after catheter ablation of atrial fibrillation

目的对比研究利伐沙班与华法林预防心房颤动(简称房颤)导管消融术后血栓形成的疗效及安全性。方法入选符合标准的226例房颤患者,随机分为治疗组和对照组,两组患者均行房颤导管消融治疗。治疗组108例导管消融术后口服利伐沙班15 mg/d或20 mg/d,对照组118例术后给予华法林抗凝,华法林均是3 mg/d起始,根据国际标准化比值调整华法林剂量。两组患者随访3个月,比较两组患者栓塞发生率、死亡率和出血发生率。结果两组均无栓塞及死亡发生。两组均无大出血及脑出血事件发生,轻度出血事件治疗组与对照组无差异(7.4%vs 8.5%,P>0.05)。结论与华法林相比,利伐沙班预防房颤导管消融术后患者栓塞事件同样有效。

Objective To compare efficacy and safety of rivaroxaban and warfarin prevention of thrombotic events after atrial fibrillation catheter ablation. Method Two hundred and twenty-six patients selected were randomly divided into the treatment group and the control group, all patients underwent catheter ablation of atrial fibrillation, the treatment group 108 cases of postoperative oral rivaroxaban 15 mg/d or 20 mg/d, the control group 118 cases of postoperative received war- farin, warfarin was 3 mg/d starting, warfarin dose adjustment in accordance with international normalized ratio. Two groups of patients were followed up for 3 months, embolism incidence,mortality, and the incidence of bleeding were observed. Results In followed up 3 months, there were no thromboembolic events occurred in the treatment group and the control group ; the treatment group and the control group had no deaths. There were no incidents of bleeding and brain hemorrhage, minor bleeding events was 7.4% in the treatment group and 8.5% in the control group, the two groups showed no signifi- cant difference （P〉0.05）. Conclusion Compared with warfarin, rivaroxaban prevented thromboembolic events after catheter ablation of atrial fibrillation in patients with equally effective, did not increase the rate of mortality and bleeding.